

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (KL-119) SIREMADLIN

PRONUNCIATION sir" e mad' lin


THERAPEUTIC CLAIM Antineoplastic

CHEMICAL NAMES

Pyrrolo[3,4-*d*]imidazol-4(1*H*)-one, 5-(5-chloro-1,2-dihydro-1-methyl-2-oxo-3-pyridinyl)-6-(4-chlorophenyl)-2-(2,4-dimethoxy-5-pyrimidinyl)-5,6-dihydro-1-(1-methylethyl)-, (6*S*)- (Source: CAS name)

(6*S*)-5-(5-chloro-1-methyl-2-oxo-1,2-dihydropyridin-3-yl)-6-(4-chlorophenyl)-2-(2,4-dimethoxypyrimidin-5-yl)-1-(propan-2-yl)-5,6-dihydropyrrolo[3,4-*d*]imidazol-4(1*H*)-one (Source: USAN Program chemical consultant)

STRUCTURAL FORMULA



MOLECULAR FORMULA C₂₆H₂₄Cl₂N₆O₄

MOLECULAR WEIGHT 555.4

TRADEMARK None as yet

SPONSOR Novartis Pharma AG

CODE DESIGNATIONS HDM201, NVP-HDM201, NVP-HDM201-NX

CAS REGISTRY NUMBER 1448867-41-1

UNII 0282IF4JC8

WHO NUMBER 10869

gbk